Castleview Partners’s Pacira BioSciences PCRX Stock Holding History

Castleview Partners’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-9	Closed	-$347	–	704
2022 Q4	$347	Buy	+9	New	+$438	﹤0.01%	596

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Castleview Partners's PCRX Position: Q1 2023 in Review

Castleview Partners sold out of Pacira BioSciences (PCRX) in Q1 2023, closing a stake of 9 shares — an estimated $347 sold.

Castleview Partners first reported a position in PCRX in Q4 2022 and held it in 1 quarter. The position peaked at $347 in Q4 2022. 267 funds tracked by Wall St. Rank hold PCRX as of Q1 2023.

Castleview Partners reported no remaining Pacira BioSciences position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 9 Pacira BioSciences shares in Q1 2023, an estimated $347.
Castleview Partners first reported a position in Pacira BioSciences in Q4 2022 and held it in 1 quarter.
Castleview Partners's Pacira BioSciences position peaked at $347 in Q4 2022.
267 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.